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Abstract
Introduction Elevated serum levels of S100β, an astrocyte-
derived protein, correlate with unfavourable neurological
outcomes following cardiac surgery, neurotrauma, and
resuscitation. This study evaluated whether pre-/postoperative
serum S100β levels correlate with unfavourable clinical and
radiological findings in patients undergoing elective meningioma
resection.
Methods In 52 consecutive patients admitted for meningioma
surgery, serum S100β levels were determined upon admission
and immediately, 24 hours, and 48 hours after surgery. All
patients underwent complete pre- and postoperative
neurological examination and mini-mental state examination.
Radiological evaluation included preoperative magnetic
resonance imaging (MRI) and postoperative computed
tomography. Tumour volume, brain edema, and bleeding volume
were calculated using BrainSCAN™ software.
Results Preoperative S100β levels did not correlate with the
tumour characteristics demonstrated by preoperative MRI (for
example, tumour volume, edema volume, ventricular asymmetry,
and/or midline shift). Preoperative serum S100β levels (0.065 ±
0.040 μg/l) were significantly lower than the levels measured
immediately (0.138 ± 0.081 μg/l), 24 hours (0.142 ± 0.084 μg/
l), and 48 hours (0.155 ± 0.119 μg/l) postoperatively (p  <
0.0001). Significantly greater postcraniotomy S100β levels
were observed with prolonged surgery (p  = 0.039),
deterioration in the mini-mental state examination (p = 0.005,
0.011, and 0.036 for pre versus immediate, 24 hours, and 48
hours postsurgery, respectively), and with postoperative brain
computed tomography evidence of brain injury; bleeding was
associated with higher serum S100β levels at 24 and 48 hours
after surgery (p = 0.046, 95% confidence interval [CI] -0.095 to
-0.001 and p = 0.034, 95% CI -0.142 to -0.006, respectively)
as was the presence of midline shift (p = 0.005, 95% CI -0.136
to -0.025 and p  = 0.006, 95% CI -0.186 to -0.032,
respectively). Edema was associated with higher serum S100β
levels immediately (p = 0.022, 95% CI -0.092 to -0.007) and at
48 hours after surgery (p = 0.017, 95% CI -0.142 to -0.026).
The degree of elevation in S100β levels at 24 and 48 hours after
surgery also correlated with the severity of midline shift and
edema.
Conclusion In patients with meningioma, serum S100β levels
perform poorly as an indicator of tumour characteristics but may
suggest ongoing postcraniotomy injury. Serum S100β levels
may serve as a potentially useful early marker of postcraniotomy
brain damage in patients undergoing elective meningioma
resection.
ANOVA = analysis of variance; CNS = central nervous system; CT = computed tomography; ICU = intensive care unit; MMSE = mini-mental state 
examination; MRI = magnetic resonance imaging.Critical Care    Vol 10 No 5    Einav et al.
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Introduction
S100β is a calcium-binding protein usually found in astro-
cytes. Its biological half-life is approximately 30 minutes [1];
hence, persistently increased levels of S100β indicate contin-
uous release of this protein from damaged tissue. Elevated
serum levels of S100β have been reported to correlate with
neurological deterioration after cardiac surgery [2,3] and with
poor likelihood of survival after hypoxia [4]. Serum protein
S100β is also a recognised marker of traumatic brain injury [5-
7] and blood-brain barrier dysfunction in the absence of appar-
ent brain injury [8]. Few studies have evaluated S100β after
surgical insult to the central nervous system (CNS); after aneu-
rysm surgery [9] and operative decompression of cord metas-
tases [10], increased serum S100β values were reported to
correlate with poor neurological outcome.
Slow-growing supratentorial brain tumours such as meningi-
omas may cause damage to adjacent neural tissue despite
their non-neural origin. Surgical access and excision of these
extra-axial tumours are generally less traumatic than in less-
accessible brain tumours or tumours of neural origin. Never-
theless, due to brain retraction and dissection, cerebral insult
may occur during surgery. A recent study of patients who
underwent meningioma resection demonstrated that patho-
logically increased serum S100β concentrations in the early
postcraniotomy period correlated with neurological deteriora-
tion [11]. In this study, however, preoperative magnetic reso-
nance imaging (MRI) parameters were not reported, tumours
were not assessed volumetrically, and a very high rate of post-
operative gross neurological deterioration occurred.
The current study was therefore conducted to examine the
correlation between serial serum S100β protein levels and
pre- and postcraniotomy MRI/computed tomography (CT)
findings and neurological deterioration in patients undergoing
meningioma resection. Revealing such associations would
potentially promote the use of preoperative S100β level as a
marker of tumour effect on brain tissue and postoperative
S100β level as a marker for early detection of ongoing post-
craniotomy brain damage.
Materials and methods
Patients
After institutional review board approval, all consecutive
patients aged 18 to 80 years who were admitted to the
Department of Neurosurgery for supratentorial meningioma
surgery (Jan. 1 to Oct. 31, 2004) were prospectively screened
for inclusion and informed consent was obtained. Excluded
were patients who refused to participate or who had a history
of chemotherapy/convulsions two weeks prior to admission,
stroke/cardiopulmonary resuscitation/head trauma three
months prior to admission, Alzheimer's disease, amyotrophic
lateral sclerosis, prior melanoma, or brain neoplasm other than
meningioma. Patients with chronic renal failure (creatinine
>200 mmol/l) were also excluded due to potential interference
with S100β clearance [12]. Patients were to be withdrawn
from the study if they suffered an episode of hemodynamic
instability (mean arterial pressure <60 mm Hg) which lasted
more than 15 minutes and was non-responsive to fluid or vaso-
pressor therapy at any time during the study period, regardless
of cause. Occurrence of postoperative cerebral ischemia/
hemorrhage was documented, but neither complication con-
stituted a criterion for withdrawal.
Perioperative management
Patients were enrolled upon admission on the day before sur-
gery. Dexamethasone (≤16 mg/day) and phenytoin/valproic
acid were prescribed individually. Anaesthesia was induced
using thiopental or propofol, fentanyl, and vecuronium and was
maintained with a balanced technique involving isoflurane,
nitrous oxide, and oxygen. Additional doses of fentanyl were
given at the anaesthesiologist's discretion. Ventilation was
adjusted to maintain a PaCO2 (partial arterial pressure of car-
bon dioxide) of 30 to 35 mm Hg. Perioperative patient moni-
toring included intra-arterial blood-pressure monitoring.
Surgery was performed by five neurosurgeons using standard
techniques to minimise neural tissue damage. A neuronaviga-
tion system was used in convexity tumours to decrease the
size of the craniotomy. In lesions in the base of skull, an extra-
dural approach was opted for to reduce brain retraction. Extu-
bation was performed in the operating room.
All patients were transferred postoperatively to the neurosur-
gical intensive care unit (ICU) for continued overnight monitor-
ing. Further monitoring and treatment in the unit were provided
at the discretion of the attending surgical ICU team, based on
individual patient needs.
Neurological evaluation
Cranial nerve function and motor, sensory, language, and cer-
ebellar function and a mini-mental state examination (MMSE)
[13] were conducted preoperatively and 48 hours after sur-
gery. All patients underwent MRI (T1, T2, T1 plus GAD [gado-
linium] and FLAIR [fluid-attenuated inversion recovery]
protocol) as part of their preoperative evaluation. CT scanning
of the brain with and without contrast material was performed
at 36 to 48 hours after surgery and repeated at the discretion
of the treating physicians. All of the images were analysed by
an independent team comprised of a neurosurgeon, radiolo-
gist, and physicist who were blinded to S100β levels and the
study results. Tumour volume and brain edema were calcu-
lated using BrainSCAN™ software (ExacTrac® computer tech-
nology; BrainLAB AG, Heimstetten, Germany), which is often
used to plan radiosurgery treatment. For the purpose of the
current study, the borders of the tumour and blood and/or
edema were marked on each slice of the CT or MRI. This ena-
bles the program to construct a 3D model of the lesion area
and measure its volume (Figure 1).Available online http://ccforum.com/content/10/5/R141
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S100β testing
Peripheral blood was sampled for S100β levels upon admis-
sion, immediately after surgery, and at 24 and 48 hours after
surgery. All samples were centrifuged and stored (-70°C).
Testing was performed using the Roche Elecsys® S100 rea-
gent kit (Roche Diagnostics GmbH, Penzberg, Germany)
(assay duration 18 minutes, measuring range 0.005 to 39 pg/
l, cross-reactivity against S100αα <1%). Less than 24 hours
prior to testing, calibration was performed per reagent kit and
control values were determined to be within the limits required
for calibration (0.206 and 2.54 μg/l). The treating physicians
were blinded to the results of the serum S100β tests.
Data collection
Study data and medical records were collected prospectively,
including patient demographics (for example, age, gender, and
past medical history), neurological examination, intraoperative
variables possibly related to surgical complexity (for example,
duration of surgery and anaesthesia, surgical plane, resection
grade, and blood loss), S100β levels, and relevant neurologi-
cal tests.
No standard criteria were found in the literature for intraopera-
tive definitions of the quality of the neurosurgical plane
afforded by the tumour or its vascularity. A tumour presenting
with a pial plane was therefore defined as a 'good' plane, and
gross tumour invasion of the pia mater and the brain was
defined as 'difficult' plane. It was assumed that dissection of
the tumour from the brain would cause greater CNS tissue
damage in the latter cases. The criteria for classification of the
degree of tumour vascularity were arbitrary and based solely
upon the senior neurosurgeon's assessment of the degree to
which bleeding interfered with resection of the tumour.
Endpoints
The study endpoints were determination of the relationship
between preoperative serum S100β levels and MRI evidence
of CNS damage and postoperative S100β levels and surgical
complexity and postoperative clinical/radiological evidence of
neural tissue injury.
Statistical analysis
The study cohort included all patients who were enrolled into
the study and who followed protocol procedures. First, the uni-
variate results of all the research variables – predictors (inde-
pendent variables) and outcome (the dependent variable) –
were examined. Categorical variables (for example, patient
gender, prior radiation/hormonal therapy, primary/recurrent
disease, and medical history) are presented with their catego-
ries and the associated percentages. Numerical variables (for
example, patient age and score in the MMSE) are presented
with their means, standard deviations, medians, and ranges.
In the second step, the relationship between the outcome var-
iables (serum S100β levels at each time point) and independ-
ent variables (variables potentially affecting these levels) was
examined and their significance (p value) is presented. The
Student t test, the Mann-Whitney test, and analysis of variance
(ANOVA) were used to examine the relationship between cat-
egorical variables (dichotomous and multiple categories,
respectively,) and S100β levels. Pearson and Kendall's tau-b
correlations were used for the relationship between continu-
ous variables and S100β levels measured in the various study
time points (for example, preoperative tumour volume and
baseline S100β levels, duration of surgery, and postoperative
S100β levels). The results of the MMSE were analysed relative
to the level of S100β as both a continuous variable and a
Figure 1
MRI/CT measurements of tumor and edema (a+b) and edema and hemorrhage (c) volumes MRI/CT measurements of tumor and edema (a+b) and edema and hemorrhage (c) volumes.Critical Care    Vol 10 No 5    Einav et al.
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dichotomous variable (deterioration versus non-deterioration)
as was the presence/degree of midline shift on the postoper-
ative CT scan. The statistical analyses were performed using
SPSS 12 software (SPSS, Inc., Chicago, IL, USA).
Results
Patients, tumour pathology, and preoperative imaging
Fifty-six patients fulfilled entry criteria and were enrolled in the
study. Three patients were excluded because they refused
participation, and one was excluded because pathology dis-
closed hemangiopericytoma. Mean age was 58.5 ± 13 years,
and 77% were female. Patient disease characteristics are pre-
sented in Table 1. All but one patient had a preoperative Glas-
Table 1
Disease characteristics of the study population (n = 52)
Concomitant diseases n Percentage
Hypertension 16 31
Hyperlipidemia 15 29
Diabetes 81 5
Thyroid disorder 6 11
Other endocrine disorder 5 10
Chronic ischemic heart disease 5 10
Chronic obstructive pulmonary disease 5 10
Liver disease 36
Metabolic disorder 3 6
Meningioma
Family history of meningioma 6 11
Prior irradiation 16 31
Prior hormonal therapy 5 10
Recurrent disease 14 27
Tumour histology Transitional 22 42
Meningothelial 12 23
Fibrous 4 8
Atypical 3 6
Othera 11 21
WHO grading 1 48 92
24 8
aSecretory, transitional and fibrous, meningiomatous, inflammatory, choroids, metaplastic, and psammomatous. WHO, World Health Organization.
Table 2
Radiological data: preoperative MRI and postoperative CT
Preoperative MRI Tumour characteristic n Percentage
Location Convexity 10 19
Parasaggital 19 36
Tuberculum sella 9 17
Anterior clinoid 5 10
Olfactory groove 3 6
Falx 3 6
Sphenoid ridge 2 4Available online http://ccforum.com/content/10/5/R141
Page 5 of 10
(page number not for citation purposes)
gow Coma Score of 15. One patient had a score of 14 due to
verbal deficit. Half of the patients scored maximal points in the
preoperative MMSE. In the majority of patients (n = 34, 65%),
pathological examination revealed transitional/meningothelial
tumour, and in 48 patients (92%), the World Health Organiza-
tion grading was 1 (Table 1). The average time from perform-
ance of the last preoperative MRI to surgery was 26.6 days.
MRI demonstrated mass effect in 67% of the patients (Table
2).
Surgery and outcome
Surgical data are presented in Table 3. The majority of surgical
procedures (n = 45, 86%) were performed via pterional or
frontal approaches. A neuronavigation system was used in
66% (21/32) of the operations that were not performed at the
base of skull and in none (0/20) of the operations that were
performed at the base of skull. The duration of surgery aver-
aged 295 ± 154 minutes (Table 3).
Postoperative (48 hours after surgery) Glasgow Coma Scores
remained 15 for all but three patients, who scored 14 (n = 2)
and 10 (n = 1). Deterioration in motor performance, senso-
rium, and language skills occurred in 10, one, and two
patients, respectively. MMSE scores decreased slightly from a
mean preoperative score of 26.6 ± 6.8 to 26.0 ± 7.1 at the
second postoperative day (p  = not significant). Sixteen
patients (31%) scored fewer points in the postoperative
MMSE than in the preoperative MMSE.
Postoperative CT scan (Table 2) revealed evidence of blood in
the surgical bed in 22 patients (42.3%) and brain edema in 35
patients (67%). The volume of bleeding was less than 1 cm3
in 12 patients, 1 to 4 cm3 in eight patients, and more than 4
cm3 in two patients. The average edema volume was 19.28 ±
23.53 cm3. In one patient, brain infarction was found. Twelve
patients (23%) had postoperative CT scan evidence of midline
shift.
Relationship between preoperative serum S100β levels 
and MRI evidence of CNS damage
Preoperative S100β levels did not correlate with tumour vol-
ume (p = 0.32), edema volume (p = 0.72), or tumour and
edema volume together (p = 0.81) as measured by MRI. Other
preoperative MRI variables such as presence of mass effect
Planum sphenoidale 1 2
Mass effect Ventricular asymmetry 23 44
Midline shift 12 23
Enhancement Homogenous 43 83
Cystic component 1 2
Dural tail 13 25
Bilateral 4 8
Multifocal 4 8
Mean Median Range
Tumour volume (cm3) 35.29 ± 29.39 29.39 2.35 to 104.20
Tumour edema-FLAIR 
(cm3)
24.83 ± 32.39 9.72 0 to 132.05
Midline shift (mm) 2.16 ± 4.29 0 0 to 15.47
Postoperative CT scanning Finding n Percentage
Residual tumour 1 2
Brain edema 35 67
Brain infarct 1 2
Midline shift 12 23
Bleeding 22 42
Mean Median Range
Midline shift (mm) 1.29 ± 2.83 0 0 to 12.35
Bleeding (cm3) 1.13 ± 4.19 0 0 to 29.68
CT, computed tomography; FLAIR, fluid-attenuated inversion recovery; MRI, magnetic resonance imaging.
Table 2 (Continued)
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(ventricular asymmetry and/or midline shift), presence of
homogenous enhancement, dural tail, or cystic component
also did not correlate with preoperative serum S100β levels.
Relationship between serum S100β levels and 
occurrence of neurosurgery
Initial serum S100β levels were 0.065 ± 0.040 μg/l (median
0.058 μg/l, range 0.009 to 0.204 μg/l) (Figure 2). These levels
increased immediately postoperatively to 0.138 ± 0.081 μg/l
(median 0.109 μg/l, range 0.022 to 0.313 μg/l) and remained
elevated throughout the study period; at 24 hours, serum lev-
els were maintained at 0.142 ± 0.084 μg/l (median 0.133 μg/
l, range 0.043 to 0.498 μg/l) and at 48 hours at 0.155 ± 0.119
μg/l (median 0.126 μg/l, range 0.000 to 0.476 μg/l). Serum
S100β levels were significantly different between pre- and all
postoperative times (p < 0.0001) (Figure 2).
Relationship between postoperative serum S100β levels 
and intraoperative variables
Serum S100β levels sampled 24 hours postoperatively corre-
lated with the duration of surgery (p  = 0.039). A difficult
surgical plane (invasion of the pia mater and brain) was asso-
ciated with higher immediate postoperative serum levels of
S100β (0.189 ± 0.08 μg/l versus 0.121 ± 0.075 μg/l, p =
0.01, 95% CI 0.017 to 0.119), but no difference was
observed at later sampling times (p = 0.102 at 24 hours and
0.198 at 48 hours).
S100β levels were compared for patients undergoing surgery
with and without use of a neuronavigation system (regardless
of surgical access route), and no difference was found
between the two groups at any of the sampling times. Postop-
erative levels of S100β were also compared between surgery
not performed in the base of skull (convexity, parasaggital, falx,
and tentorial) and surgery performed in the base of skull (olfac-
tory groove, tuberculum sella, and anterior clinoid), and no
significant difference was found. ANOVA did not demonstrate
a difference in S100β levels at any of the examined times
between meningiomas with different degrees of vascularity
(high, medium, and low).
Relationship between postoperative S100β levels and 
postoperative evidence of neural tissue injury
Clinical examination
Deterioration in motor performance or decreased sensorium
was not associated with higher postoperative elevations of
serum S100β. Serum S100β levels were higher only 48 hours
after surgery in patients with evidence of deterioration in lan-
guage skills (no deterioration 0.147 ± 0.111 μg/l, deteriora-
tion 0.325 ± 0.205 μg/l [p  = 0.037, 95% CI -0.344 to -
0.012]). Overt clinical deterioration in neurological perform-
ance was associated with significantly higher serum S100β
levels immediately after surgery (no deterioration 0.116 ±
0.071 μg/l, deterioration 0.168 ± 0.086 μg/l [p = 0.031, 95%
CI -0.100 to -0.005]) but not later.
Table 3
Surgical data
n Percentage
Approach Pterional 24 46
Frontal 21 40
Parietal 7 14
Navigation Yes 21 40
No 31 60
Extent of excision (Simpson grade) [27] 1 – Macroscopically complete removal of dura, bone 39 75
2 – Macroscopically complete removal, dural coagulation 11 21
3 – Complete tumour resection, dura not coagulated 2 4
Plane Difficult (invasion of the pia mater and brain) 14 27
Good (pial plane) 38 73
Tumour vascularity High 2 4
Medium 29 56
Low 21 40
Mean ± SD Median Range
Length of anesthesia (minutes) 385 ± 159 355 195 to 870
Length of surgery (minutes) 295 ± 154 240 75 to 765
Blood loss (cc) 345 ± 189 300 50 to 1,000
SD, standard deviation.Available online http://ccforum.com/content/10/5/R141
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MMSE
The immediate and 24-hour postoperative S100β levels were
higher among patients whose scores in the MMSE decreased
postoperatively when compared with patients who retained or
improved their capabilities (Figure 3). The severity of deterio-
ration in the results of the MMSE correlated with the degree of
elevation of postoperative serum S100β levels at all the sam-
pling times (immediately [p = 0.005], 24 hours [p = 0.011],
and 48 hours [p = 0.036] after surgery).
Radiology
Postoperative CT scan evidence of bleeding was associated
with higher serum S100β levels at 24 and 48 hours after sur-
gery (Figure 4) as was the presence of midline shift (0.126 ±
0.066 μg/l versus 0.206 ± 0.116 μg/l, p = 0.005, 95% CI -
0.136 to -0.025 and 0.129 ± 0.104 μg/l versus 0.238 ±
0.130 μg/l, p = 0.006, 95% CI -0.186 to -0.032, respectively).
The degree of elevation in S100β levels also correlated with
the severity of midline shift at these time points (p = 0.01 and
0.002, respectively). Edema was associated with higher
serum S100β levels immediately after surgery (p  = 0.022,
95% CI -0.092 to -0.007) and at 48 hours after surgery (p =
0.017, 95% CI -0.142 to -0.026). The severity of edema
correlated with the degree of elevation of serum S100β levels
at all sampling times (p = 0.05 immediately, p = 0.005 at 24
hours, and p < 0.001 at 48 hours after surgery). The serum
S100β levels of the single patient who had postoperative CT
scan evidence of infarction were significantly higher in the
immediate postoperative (p  = 0.019, 95% CI -0.342 to -
0.034) and 24-hour (p  = 0.009, 95% CI -0.3 to -0.048)
postoperative measurements when compared with patients
who had no CT scan evidence of bleeding or infarction.
Discussion
This study is the first systematic examination of the relationship
between serum S100β levels and MRI evidence of CNS dam-
age caused by the presence of a homogenous group of extra-
axial supratentorial tumours. It is also the first investigation of
the link among postcraniotomy serum S100β levels, MMSE
performance, and volumetric CT scan evidence of CNS
compromise.
The data confirm that this marker performs poorly for charac-
terisation and follow-up of this type of tumour. A correlation
was found, however, between immediate postcraniotomy
serum S100β levels and deterioration in performance of the
MMSE. Persistently elevated early postoperative levels of
serum S100β were also associated with postoperative CT
scan evidence of bleeding, edema, or midline shift, suggesting
a component of ongoing active release of S100β from glia
accompanying secondary brain insult. This finding is of partic-
ular importance because the rise of this biomarker precedes
clinical findings; patients are often incapable of undergoing
complex clinical neurological testing at this stage.
Preoperative S100β levels did not correlate with either tumour
and/or edema volume. It would be expected that a mass press-
ing the surrounding brain could have resulted in some S100β
release. Plausible explanations for this finding include the slow
lesion dynamics of this type of tumour; slow-growing tumours
may cause less blood-brain barrier disruption, and the damage
to the structural network supporting the neurons may be so
gradual that even if S100β were released, current techniques
would not be sensitive enough to distinguish the level between
Figure 2
Serum S100β levels (average in micrograms per litre ± 95% confi- dence interval) at the various sampling times Serum S100β levels (average in micrograms per litre ± 95% confi-
dence interval) at the various sampling times.
Figure 3
Postoperative serum S100β levels (average in micrograms per litre ±  95% confidence interval) with/without deterioration in mini-mental state  examination (MMSE) performance Postoperative serum S100β levels (average in micrograms per litre ± 
95% confidence interval) with/without deterioration in mini-mental state 
examination (MMSE) performance.Critical Care    Vol 10 No 5    Einav et al.
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persons with no CNS lesion and those with a lesion causing a
gradual mass effect. Molecular mechanisms for neuronal reor-
ganisation (that is, plasticity) may also involve signaling cas-
cades that affect astrocytes. Finally, S100β may have a role in
processes occurring during acute but not chronic injury; it was
recently demonstrated that S100β mRNA expression is
potently downregulated after 12 and 24 hours of oxygen,
serum, and glucose deprivation. Moreover, prolonged oxygen,
serum, and glucose deprivation (for 48 hours)isassociated
with a significant reduction of S100β release at later time inter-
vals [14].
S100β levels were affected by the quality of surgical plane but
not by the need to resect at a less-accessible tumour location
(convexity located versus deep-seated). This may stem from
the use of complex neurosurgical techniques intended to min-
imise retraction over the parenchyma of the brain (that is,
extensive bone work, large craniotomies, extensive drilling of
the skull base, and opening of the basal cisterns).
Our results are in agreement with previous work by Stranjalis
et al. [11], who demonstrated in patients undergoing meningi-
oma resection that the increased S100β level area under the
curve up to seven days postcraniotomy was the most
significant predictor for postoperative neurological deteriora-
tion and that those patients with increased postoperative
S100β values had greater risk of poor outcome up to six
months after surgery. In their study, however, preoperative MRI
was not used, tumours were not assessed volumetrically, and
a relatively high rate of gross neurological deterioration
occurred postoperatively (immediate 50%, 6 months 30%).
In a study of operative decompression in patients suffering
paresis due to metastatic spinal cord compression, functional
outcome also correlated with S100β levels [10]. Patients with
Figure 4
Serum S100β levels (average in micrograms per litre micrograms per litre is correct. ± 95% confidence interval [CI]) with/without postoperative  computed tomography scan (CTS) evidence of bleeding Serum S100β levels (average in micrograms per litre micrograms per litre is correct. ± 95% confidence interval [CI]) with/without postoperative 
computed tomography scan (CTS) evidence of bleeding.Available online http://ccforum.com/content/10/5/R141
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favourable outcomes had serum levels of S100β which were
either normal all the time or increased initially but normalised
within two to three days, whereas patients who had an unfa-
vourable outcome also had continuously elevated levels (that
is, levels either increased further or decreased slowly during
14 days). Elevated 10-day S100β levels were also predictive
of the appearance of a new neurological deficit after surgery
for aneurysmal subarachnoid hemorrhage [9]. The results from
this study, in agreement with our study, confirmed that ele-
vated serum S100β values after subarachnoid aneurismal
hemorrhage correlate with postoperative CT scan findings
such as infarction and vasospasm. Finally, serum S100β levels
correlated with the size of the tumour-brain contact surface,
which was closely related to the dimension of the surgical
trauma, and with postoperative CNS damage caused by neu-
rosurgical manipulation [15]. In the current study, use of
neuronavigation did not moderate the increase observed in
serum S100β levels but this finding may be related to surgical
technique.
Correlations between deterioration in performance of the
MMSE and elevations in S100β levels, similar to those found
in the present study, have been reported after cardiopulmo-
nary bypass surgery [2,3]. This has not been demonstrated
after cardiac arrest and resuscitation [16], possibly due to the
length of time that had elapsed between the event and MMSE
testing or the small number of survivors available for testing.
There are several limitations to this study. Long-term follow-up
to correlate serum S100β values with late outcome was not
performed. One should also exercise caution in using serum
S100β as the sole marker of brain damage; this protein may
be released from injured tissues outside the brain, particularly
from the heart, or mediastinum [17,18]. Experimental data in
rat tissue found S100β in adipose, skin, and testicular tissue,
albeit in significantly lower concentrations than in brain tissue
[19]. Immunocytochemical approaches also demonstrated
S100β in damaged skeletal muscle [20] and adipose tissue
[21], and S100β protein has also been demonstrated in villous
and intermediate trophoblast cells of the normal human pla-
centa [22-24]. Rasmussen et al. [25] noted an increase in
S100β 24 and 48 hours even after elective abdominal surgery
and observed that this rise may be related to the appearance
of postoperative delirium. S100β increases in the postopera-
tive period may thus indicate more than one typ e of CNS
derangement. S100β may also be involved in reparative proc-
esses after brain damage [26]. Sampling was limited to 48
hours after surgery although previous studies indicated ongo-
ing damage for more than five days. Further sampling may
have yielded additional information. Finally, in the current
study, the S100β levels of patients who had postoperative CT
scan evidence of bleeding overlapped with the levels of those
who had none and postoperative edema was not consistently
associated with elevated levels of S100β. Studies including
larger sample populations are required to substantiate or dis-
prove the relationship between these CNS pathologies and
elevations in serum S100β levels.
Conclusion
In patients with meningioma, serum S100β levels perform
poorly as an indicator of tumour characteristics but may pro-
vide an early sign of postcraniotomy injury. Although the rele-
vance of extracranial sources of S100β and the possible
implications of participation of S100β in reparative processes
after brain damage demand further investigation, the data sug-
gesting that S100β protein does have potential as a prognos-
tic clinical tool are increasing. The current study provides
further substantiation to the mounting pool of data that serum
S100β may be used as an early biomarker of acute neural tis-
sue injury in the postoperative setting.
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